In order to be the global leader in wound care, HEALTHPOINT is committed to investing in the discovery and development of scientifically sound, cost-effective pharmaceuticals and biologics.
Our experienced Research and Development team helps accomplish our mission by bringing novel biologics and pharmaceuticals to market. A determined focus on improving clinical and quality-of-life outcomes in patients affected by wounds drives our work in cell sciences, antimicrobials, biologics, and small molecules.
The continuing progress and success of these endeavors make HEALTHPOINT a growing presence in the scientific community. In 2008 and 2009 alone, HEALTHPOINT scientists presented 26 posters at the Symposium on Advanced Wound Care, the Wound Healing Society Meeting (eliciting 12 Blue Ribbon Award nominations), and the World Union of Wound Healing Societies.
HEALTHPOINT is currently investing more than $100 million in Research and Development over the next five years to continue advancing the science of wound care. Our strategic plan includes a balanced, sustainable pipeline of drugs, biologics, and advanced medical devices. With the innovation and creativity of our R&D team, HEALTHPOINT is quickly becoming a global leader in wound care.
Currently, HEALTHPOINT has numerous studies in all stages of development, from pre-clinical to Phase III.